Effects of paricalcitol combined with hemodiafiltration on bonemetabolism-related indexes in patients with diabetic nephropathy and chronic renal failure
作者机构：Department of NephrologyCangzhou Central HospitalCangzhou 061000Hebei ProvinceChina
出 版 物：《世界糖尿病杂志:英文版(电子版)》 (World Journal of Diabetes)
年 卷 期：2023年第14卷第9期
页 面：1385-1392页
核心收录：
学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Paricalcitol Hemodiafiltration Diabetic nephropathy Chronic renal failure Serum calcium Serum phosphorus Intact Paricalcitol hormone
摘 要：BACKGROUND Diabetic nephropathy(DN)is frequently seen in the development of diabetes mellitus,and its pathogenic factors are *** current treatment is controversial,and there is a lack of a relevant efficacy prediction *** To determine the effects of paricalcitol combined with hemodiafiltration on bonemetabolism-related indexes in patients with DN and chronic renal failure(CRF),and to construct an efficacy prediction *** We retrospectively analyzed 422 patients with DN and CRF treated in Cangzhou Central Hospital between May 2020 and May *** selected 94 patients who met the inclusion and exclusion *** were assigned to a dialysis group(n=45)and a joint group(n=49)in relation to therapeutic *** clinical efficacy of the two groups was compared after *** changes in laboratory indexes after treatment were evaluated,and the two groups were compared for the incidence of adverse *** predictive value of laboratory indexes on the clinical efficacy on patients was *** The dialysis group showed a notably worse improvement in clinical efficacy than the joint group(P=0.017).After treatment,the joint group showed notably lower serum levels of serum creatinine,uric acid(UA)and blood urea nitrogen(BUN)than the dialysis group(P0.05).According to least absolute shrinkage and selection operator regression analysis,UA,BUN,phosphorus and PINP were related to treatment *** to further comparison,the non-improvement group had higher risk scores than the improvement group(P0.0001),and the area under the curve of the risk score in efficacy prediction was *** For treatment of CRF and DN,combined paricalcitol a
维普期刊数据库